The first patient has been dosed in a Phase 2 clinical trial, VANGUARD, evaluating PhaseBio Pharmaceuticals’ (NASDAQ:PHAS) PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).
The primary endpoint of the 210-subject study is days alive and free of respiratory failure through day 28. The estimated completion date is December.
PB1046 is a subcutaneously administered (once/week) VIP receptor agonist that targets VPAC receptors in the cardiovascular, pulmonary and immune systems. VIP is a neurohormone known to have anti-inflammatory, antifibrotic and potent bronchodilatory and immunomodulatory effects in the respiratory system via the regulation of pro-inflammatory proteins (cytokines).
https://seekingalpha.com/news/3592056-mid-stage-study-underway-on-phasebios-pb1046-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.